Brecanavir
Clinical data | |
---|---|
ATC code | none |
Identifiers | |
| |
CAS Number | 313682-08-5 |
PubChem (CID) | 5743186 |
ChemSpider | 4675192 |
UNII | E367I8C7FI |
ChEMBL | CHEMBL206031 |
Chemical and physical data | |
Formula | C33H41N3O10S2 |
Molar mass | 703.82 |
3D model (Jmol) | Interactive image |
| |
| |
(what is this?) (verify) |
Brecanavir (INN; codenamed GW640385) is a protease inhibitor which has been studied for the treatment of HIV.[1]
On December 2006, its developer, GlaxoSmithKline discontinued further development because of insurmountable issues regarding formulation.[2]
See also
References
- ↑ Hazen R, Harvey R, Ferris R, et al. (September 2007). "In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV". Antimicrob. Agents Chemother. 51 (9): 3147–54. doi:10.1128/AAC.00401-07. PMC 2043237. PMID 17620375.
- ↑ "GlaxoSmithKline discontinues clinical development of investigational protease inhibitor brecanavir (640385)" (Press release). GlaxoSmithKline. 2006-12-18. Retrieved 2008-06-11.
This article is issued from Wikipedia - version of the 8/12/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.